Monitor for future licensing deals, regulatory approvals, or commercial partnerships around MGX-0024, especially in key markets like India. The current market cap ($6M) suggests high sensitivity to any future monetization news.
Price Chart
Executive Summary
Mangoceuticals, Inc. (MGRX) announced the filing of a PCT international patent application for its antiviral animal feed additive technology, MGX-0024, following positive trial results. The move aims to secure global IP protection in over 150 countries, supporting future commercialization in markets like India, though no financial or transactional deal terms were disclosed.
Key Facts
- Mangoceuticals filed a PCT international patent application (P-641039-PC) on February 26, 2026, for MGX-0024, an antiviral animal feed and drinking water additive.
- The PCT filing claims priority from a U.S. provisional patent filed February 26, 2025.
- Technology showed zero respiratory-related mortality in 29,000 birds in field trials and prophylactic efficacy against H5N1 in controlled studies.
- U.S. patent already granted (No. 11,517,523); national patents pending or granted in EU, Canada, China, India, Australia, and Japan.
- No acquisition, partnership terms, or financial deal value was disclosed — this is an IP filing, not a transactional M&A event.
Financial Impact
No immediate financial impact disclosed; potential long-term value if MGX-0024 is commercialized globally.
Risk Factors
- No guarantee of patent grants in PCT member countries.
- MGX-0024 is not yet commercialized; regulatory, manufacturing, or adoption hurdles may arise.
- MGRX remains a micro-cap stock with structural risks including Nasdaq listing compliance and shareholder dilution from convertible securities.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251266 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $0.3834 $0.2801 | ▲ +26.94% | ▲ +25.45% | $0.2491 (+35.03%) |
Oct 9, 2026 17d ago | 424B5 | $0.3834 $0.2801 | ▲ +26.94% | ▲ +25.45% | $0.2491 (+35.03%) |
Oct 6, 2026 21d ago | SC 13D/A | $0.4500 $0.3716 | ▼ −17.42% | ▼ −17.28% | $0.2491 (−44.64%) |
Oct 1, 2026 25d ago | 8-K | $0.4805 $0.4324 | ▼ −10.01% | ▼ −11.31% | $0.2491 (−48.16%) |
Jul 30, 2026 12w ago | 425 | $0.2936 $0.5270 | ▲ +79.50% | ▲ +75.87% | $0.2491 (−15.16%) |
Jul 30, 2026 12w ago | 8-K | $0.2936 $0.5270 | ▲ +79.50% | ▲ +75.87% | $0.2491 (−15.16%) |
Mar 6, 2026 33w ago | Press Release | $0.3470 $0.4040 | ▲ +16.43% | ▲ +17.78% | $0.2491 (−28.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers